Nature Reviews Drug Discovery

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)

Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal Mar 01, 2025 pp. 171-189 10.1038/s41573-024-01084-2

The targeted protein degradation landscape

Kelly Farley, Souparno Bhattacharya, Jon Cleland et al. Mar 01, 2025 pp. 164-165 10.1038/d41573-024-00187-0

Can large, simple trials bring drug developers back to common diseases?

Asher Mullard Mar 01, 2025 pp. 162-163 10.1038/d41573-025-00030-0

First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon

Ken Garber Mar 01, 2025 pp. 155-157 10.1038/d41573-025-00029-7

Approvals by the China NMPA in 2024

Xiecheng Zhi, Qiu Li, Liming Shao Mar 01, 2025 pp. 160-161 10.1038/d41573-025-00028-8

FDA approves TROP2-targeted antibody–drug conjugate for breast cancer

Asher Mullard Mar 01, 2025 pp. 159-159 10.1038/d41573-025-00027-9

Directing autophagy to degrade cell surface receptors

M. Teresa Villanueva Mar 01, 2025 pp. 169-169 10.1038/d41573-025-00026-w

Designer proteins take the bite out of snake venom

Katie Kingwell Mar 01, 2025 pp. 167-167 10.1038/d41573-025-00025-x

Peptide blocks phase separation and oncogenic transcription

Alex Eccleston Mar 01, 2025 pp. 168-168 10.1038/d41573-025-00023-z

New target to tackle coronaviruses

Sarah Crunkhorn Mar 01, 2025 pp. 170-170 10.1038/d41573-025-00021-1

PKC modulator promotes remyelination

Sarah Crunkhorn Mar 01, 2025 pp. 170-170 10.1038/d41573-025-00020-2

Designing proteins targeting neosurfaces

Sarah Crunkhorn Mar 01, 2025 pp. 170-170 10.1038/d41573-025-00019-9

Degrading aurora kinase A in neuroblastoma

Sarah Crunkhorn Mar 01, 2025 pp. 170-170 10.1038/d41573-025-00018-w

FDA approves new non-opioid pain drug

Katie Kingwell Mar 01, 2025 pp. 158-158 10.1038/d41573-025-00022-0

J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio

Asher Mullard Mar 01, 2025 pp. 159-159 10.1038/d41573-025-00015-z

Base editing reduces prion protein

Sarah Crunkhorn Mar 01, 2025 pp. 169-169 10.1038/d41573-025-00016-y

Chemical engineering of CRISPR–Cas systems for therapeutic application

Halle M. Barber, Adrian A. Pater, Keith T. Gagnon et al. Mar 01, 2025 pp. 209-230 10.1038/s41573-024-01086-0

Open Targets: 10 years of partnership in target discovery

David G. Hulcoop, Gosia Trynka, Ellen M. McDonagh Mar 01, 2025 pp. 153-154 10.1038/d41573-024-00204-2

Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer

Sébastien Viel, Eric Vivier, Thierry Walzer et al. Mar 01, 2025 pp. 190-208 10.1038/s41573-024-01098-w